Atossa Therapeutics Seeks Shareholder Approval for Future Reverse Stock Split to Maintain Nasdaq Listing
ATOS sits 42% above its 52-week low of $3.76.
Summary
Atossa Therapeutics is asking shareholders to approve a future reverse stock split (2:1 to 20:1) as a precautionary measure to ensure continued Nasdaq listing compliance, following a 15:1 reverse split in February 2026.
Key Events · Corporate Governance and Compliance · ATOS
-
Proposal for Future Reverse Stock Split
Shareholders will vote on authorizing the Board to implement a reverse stock split at a ratio between 2:1 and 20:1 within 12 months of approval.
-
Nasdaq Compliance Precaution
This measure is a precaution to maintain Nasdaq's minimum bid price requirement, especially after a 15:1 reverse stock split was effected on February 2, 2026.
-
Risk of Immediate Delisting
The company notes that if it falls out of compliance again within 12 months of the prior split, it may not receive a grace period and could face immediate delisting.
-
Increased Authorized Shares
A reverse split would effectively increase the number of authorized but unissued shares, providing flexibility for future capital raises or acquisitions.
Analysis · ATOS · Life Sciences
Atossa Therapeutics is seeking shareholder approval for a potential future reverse stock split, with a ratio ranging from 2:1 to 20:1. This is presented as a precautionary measure to provide the Board with flexibility to maintain Nasdaq minimum bid price compliance. The company recently completed a 15:1 reverse stock split on February 2, 2026. The filing explicitly highlights that if the company falls out of compliance again within 12 months of the previous split, it may face immediate delisting without a grace period. This proposal signals ongoing concerns about the company's stock price stability and its ability to meet listing requirements, which could impact investor confidence and future capital raising efforts. The authorization would also increase the number of authorized but unissued shares, providing additional capital raising flexibility.
At the time of this filing, ATOS was trading at $5.33 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $45.9M. The 52-week trading range was $3.76 to $19.35. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.